Publications
5491 Results
- Journal / Conference
- Clinical Cancer Research Apr 14;28(8):1690-1700
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35176136
- PMC
- PMC9093780
- Study Number(s)
- CTSU/C80405
Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer of CALGB/SWOG 80405 (Alliance) treated with standard-of-care combinations of bevacizumab and cetuximab
- Journal / Conference
- Frontiers in Oncology Jan 14;11:808715
- Year
- 2022
- Research Committee(s)
- Cancer Control
- PMID
- PMID35096612
- PMC
- PMC8795906
- Study Number(s)
- SWOG-9217
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial
- Journal / Conference
- Prostate Cancer and Prostatic Diseases Apr;25(4):755-761
- Year
- 2022
- Research Committee(s)
- Cancer Control and Prevention and Epidemiology
- PMID
- PMID35152271
- PMC
- PMC9372232
- Study Number(s)
- SWOG-9217
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
- Journal / Conference
- Lancet Oncology Feb;23(2):259-269
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35038433
- Study Number(s)
- CTSU/R1010
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
- Journal / Conference
- Journal of Geriatric Oncology May;13(4):469-479
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35105521
- PMC
- PMC9058225
- Study Number(s)
- CTSU/C80405
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Immune Gene Expression Signatures associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), plenary, oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1616